California's COVID-19 stay-at-home order associated with affected cervical cancer screening rates
Did pandemic lockdowns cause women to miss cervical cancer screenings?
An observational report from a large Southern California health system found that cervical cancer screening rates for women aged 21-65 were …
California's pandemic lockdowns likely caused women to miss cervical cancer screenings, delaying early detection of pre-cancerous changes.
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
Doctors describe treatment response in rare case of dual-lesion lymphoma
A case report and systematic review describes a 65-year-old female with rare dual-lesion DLBCL featuring both GCB and ABC subtypes. After in…
Doctors treated a woman with two different rare lymphoma types in her brain and muscle, achieving stability after adjusting her chemotherapy…
Meta-analysis finds 32% higher breast cancer mortality hazard for Indigenous women despite lower incidence
Indigenous women face higher breast cancer mortality despite lower incidence rates
A systematic review and meta-analysis of 61 studies across seven countries found Indigenous women had lower breast cancer incidence but a 32…
Indigenous women have lower breast cancer rates but face a 32% higher risk of dying from the disease compared to non-Indigenous women.
Observational report examines breast cancer survival rates in US males
Study examines survival rates for men with breast cancer in the United States
An observational report examined breast cancer survival in males in the United States. The report did not provide specific survival rates, s…
A new report describes the survival rate of males diagnosed with breast cancer in the United States.
Hypofractionated Radiotherapy Shows High Disease Control in Melanoma Brain Metastases
Can a gentler radiation schedule help control melanoma that has spread to the brain?
A retrospective single-center study of 26 patients with melanoma brain metastases found hypofractionated radiotherapy achieved 96% disease c…
A gentle radiation schedule controlled bleeding brain tumors in 100% of cases while shrinking most melanoma growths without severe side effe…
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor
What happens when a rare cancer returns? One young woman's story offers a clue.
A case report describes a 23-year-old woman with neurofibromatosis type 1 and Malignant Triton Tumor. After surgical resection and recurrenc…
A 23-year-old woman with a rare chest tumor found disease stabilization after surgery failed, using a mix of chemotherapy, targeted therapy,…
PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review
Review explores potential kidney cancer treatment target and challenges
A review article summarizes literature on the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC). The pathway is often abnormally…
Kidney cancer tumors often overactivate a cell pathway that drives growth and spreading, prompting doctors to explore blocking it with new d…
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer
FDA approves a new targeted cancer drug called Krazati for lung and colorectal cancers.
The FDA has approved Krazati as a single agent for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least…
FDA approves Krazati, a new targeted drug for lung and colorectal cancers with a specific genetic change after other treatments fail.
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea.
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy
The FDA approved a new treatment for a type of blood cancer called multiple myeloma.
The FDA has approved Elrexfio, a bispecific BCMA-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myelom…
A new FDA-approved treatment helps shrink multiple myeloma in patients who have already tried at least four other therapies.
Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC
For advanced nasopharyngeal cancer, can immune therapy help? New analysis shows what patients might expect.
A meta-analysis of 9 studies (883 patients) found PD-1/PD-L1 inhibitors for recurrent/metastatic nasopharyngeal carcinoma yielded a median O…
For advanced nasopharyngeal cancer, immune therapy helps 43% stay cancer-free for a year while 80% survive, though side effects affect 90% o…
Photobiomodulation reduces severe oral mucositis (RR 0.46) and pain (RR 0.35) in head and neck cancer patients
Can light therapy ease the brutal mouth sores and pain of head and neck cancer treatment? A review of 30 studies suggests it can.
A meta-analysis of 30 RCTs (n=1748) found photobiomodulation significantly reduced the risk of severe oral mucositis (RR 0.46, 95% CI: 0.29-…
A review of 30 studies shows light therapy significantly reduces severe mouth sores and pain for head and neck cancer patients while improvi…